https://www.fda.gov/media/161378/download
B. Riley Securities Maintains Buy on Allogene Therapeutics, Lowers Price Target to $18
B. Riley Securities analyst Kalpit Patel maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price target from $21 to $18.